[서울=뉴스핌] Reporter Kim Joon-hee = Naivek, a company specializing in peptide fusion biotechnology, discusses the peptide drug delivery platform and its main pipeline at the ‘2021 JP Morgan Healthcare Conference’ with global pharmaceutical companies.
Naivek announced on the 6th that it will participate in the ‘2021 JPMorgan Healthcare Conference’, which is held online from the 11th to the 14th (local time). At this conference, Naivek plans to present the results of a lung cancer inducing orthotopic tumor model study of’K-RAS mutation inhibitor’ among anticancer drugs based on the peptide drug delivery platform’NIPEP-TPP’.
 |
| [로고=나이벡] |
In addition, the company plans to conduct a one-on-one partnership with major pharmaceutical companies on the results of research on oral and injection treatments in various pipelines, such as osteoporosis treatment, lung fibrosis treatment, and inflammatory bowel disease treatment.
A Naivek official said, “We plan to conduct follow-up discussions and technical discussions through corporate partnerships with major pharmaceutical companies on Naivek’s drug delivery platform NIPEP-TPP and various peptide-based pipelines.” As there are no temporal and spatial constraints, practical managers of each pipeline can directly participate in the meeting, so a more detailed discussion is expected.
Through this conference, Naivek expects to be able to proceed with additional contracts with global pharmaceutical companies in the future, starting from this event, by conducting more detailed follow-up discussions with global big pharmaceuticals that had previously discussed.